May 15, 2019 / 10:40PM GMT
Jason Matthew Gerberry - BofA Merrill Lynch, Research Division - MD in US Equity Research
Our next company presenter -- my name is Jason Gerberry. I'm the U.S. pharma analyst. I'm pleased to be introducing Lexicon Pharmaceuticals. Lonnel Coats, CEO, has a presentation.
So Lonnel, the floor is yours.
Lonnel Coats - Lexicon Pharmaceuticals, Inc. - President, CEO & Director
Thank you, Jason. Thank you very much. Today, I will be making forward-looking statements that may contain risk, all of our risks covered in our SEC filings, which I would suggest you read. I always make these presentations on behalf of the extraordinary men and women at Lexicon who toil daily to advance our medicines in the hands of patients. So let me jump right in.
So Lexicon's scientific platform now has produced 2 commercial products and a pipeline of innovative drugs, the first of which was introduced as XERMELO in 2017 here in the United States and then our collaborator, Ipsen, introduced XERMELO in its territories around the world, more specifically in Europe, and
Lexicon Pharmaceuticals Inc at Bank of America Merrill Lynch Health Care Conference Transcript
May 16, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers